Stay updated on CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Sign up to get notified when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.

Latest updates to the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedA banner about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” was removed from the top of the page.SummaryDifference1%

- Check17 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434 and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a new Revision: v3.7.0. A large set of key study documents and links, including the Informed Consent Form (ICF), Statistical Analysis Plan (SAP), Study Protocol, and IPD sharing information, were removed.SummaryDifference24%

Stay in the know with updates to CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.